
Squawk on the Street Cramer's Morning Take: Eli Lilly 4/30/24
Apr 30, 2024
Jim and Jeff discuss Eli Lilly's strong quarterly profit and increased guidance, focusing on high sales of Mounjaro and Zepbound. They also touch on market trends, revenue outlook, and expansion plans, reflecting optimism amidst a temporary shortage issue.
Chapters
Transcript
Episode notes
